NCNeetu Chawla

Neetu Chawla

*This is an algorithmically generated author record based on publicly available information.

Research Subjects


Neetu Chawla has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Burden of Hospitalizations in Four Adolescent and Young Adult Cancer Survivor Populations in the United States, 2006 to 2020

    by Karen J. Wernli, Eric C. Haupt, Andrew B. Smitherman, Thearis Osuji, Ernest Shen, Neetu Chawla, Mallory Casperson, Anne C. Kirchhoff, Cecile A. Laurent, Kathryn J. Ruddy, et al.

    Background: We describe hospitalization rates in adolescent and young adult (AYA) cancer survivors 2 to 5 years (Y2–Y5) from diagnosis. Methods: Observational study of AYA cancer survivors diagnosed 2006 to 2020 was conducted in two healthcare systems [Kaiser Permanente Southern California (KPSC; n = 7,889) and Kaiser Permanente Northern California (KPNC; n = 7,338)] and two states [California (47,302) and Utah (n = 7,935)]. Hospitalizations were ascertained from electronic health records and statewide administrative records and stratified into pregnancy-related and other indications. Hospitalization rates were calculated by cohort. We estimated patient factors associated with hospitalizations using a Poisson model. Results: Most AYA survivors were women (∼64% of all cohorts), with a mean age of ∼31 years at diagnosis, and were predominantly non-Hispanic White (range, 35.1%–81.2%) or Hispanic (range, 14.3%–40.6%). Overall, 21% to 24% of AYA survivors experienced ≥1 hospitalization. Unadjusted hospitalization rates declined from Y2 [range, 155.1–243.4 per 1,000 person-years (PY)] to Y5 (range, 105.8–132.0 PY; P trend < 0.0001 in all cohorts). Factors associated with increased non–pregnancy-related hospitalizations were [range of relative risks (RR)] non-Hispanic Black race/ethnicity (RR, 1.46–1.66 vs. non-Hispanic White); public insurance (RR, 1.57–1.93 vs. commercial/military); receipt of chemotherapy (RR, 1.51–1.81); and cancer type—breast cancer (RR, 1.69–1.97), cervical cancer (RR, 2.30–3.31), colorectal cancer (RR, 2.76–3.66), acute lymphoblastic leukemia (ALL; RR, 2.89–5.19), acute myeloid leukemia (AML; RR, 2.11–5.05), and sarcoma (RR, 2.70–4.96; all vs. thyroid). Conclusions: Although hospitalizations decline as the time from diagnosis elapses across health system settings and states, nearly one in five AYA cancer survivors experience hospitalization in early survivorship. Impact: Hospitalization rates remain elevated in some AYA patient subgroups in early survivorship, highlighting the need to identify AYAs at risk to mitigate unanticipated hospitalizations and costs.